Hepln-13

• Description :

  Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 μM. Hepln-13 can be used for the research of metastatic prostate cancer[1].

• Product Name Alternative :

  Clodantoin, Xenazoic acid; CV58913

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Ser/Thr Protease

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/hepln-13.html

• Purity :

  99.34

• Solubility :

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles :

  BrC1=CC=C(C=C1)C(N2)NC3=C4C2=CC=CC4=CC=C3

• Molecular Formula :

  C17H13BrN2

• Molecular Weight :

  325.20

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Tang X, et al. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget. 2014;5 (5) :1352-1362.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [64369-13-7]